Melphalan

🧮 Dose calculator

Multiple myeloma · Regimen source: FDA Evomela · 2.1

• • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Evomela · 2.1
• • Weight above 130% of ideal: compute BSA from adjusted ideal body weight. FDA Evomela · 2.1

Enter age and weight.

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Evomela · 8.1

  “Risk Summary Based on its mechanism of action, Evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see Clinical Pharmacology ( 12.1 )] .”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Evomela · 8.2

  “Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing children from melphalan, breastfeeding is not recommended during treatment with Evomela and for one week after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Evomela · 8.4

  “Safety and effectiveness have not been established in pediatric patients.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Evomela · 8.5

  “No overall differences in safety or effectiveness were observed between these subjects and younger subjects.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Evomela · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Evomela and for 6 months after the last dose.”